Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.33 |
| ▸ | SPR | P35270 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23976390 | 0.95 | PDE10A (0.33) | PDE10ASPRHPGD | |
| SCHEMBL26229044 | 0.92 | SYK (0.36) | SYKPDE10ASPRHPGD | |
| SCHEMBL26229002 | 0.91 | SYK (0.35) | SYKPDE10ASPRHPGD | |
| SCHEMBL23975667 | 0.90 | SYK (0.37) | SYKPDE10ASPRHPGDROCK2 | |
| SCHEMBL26228982 | 0.90 | PDE10A (0.33) | SYKPDE10ASPRHPGDROCK2 | |
| SCHEMBL26229022 | 0.89 | MAPT (0.39) | SYKPDE10AHPGD | |
| SCHEMBL23976419 | 0.86 | PDE10A (0.34) | SYKPDE10ASPRHPGD | |
| SCHEMBL30118627 | 0.86 | PDE10A (0.34) | SYKPDE10ASPRHPGD | |
| SCHEMBL23976726 | 0.86 | PDE10A (0.34) | PDE10ASPRHPGD | |
| SCHEMBL30118621 | 0.86 | PDE10A (0.34) | PDE10ASPRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | HAMP, SLC40A1, FANCI | SYK 4185/4885PDE10A 2677/4885SPR 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.